Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced its upcoming presentations at several investor and scientific conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced its upcoming presentations at several investor and scientific conferences. Initial data from the Phase 1 Trial of MP0317 for solid tumors will be showcased at the Society for Immunotherapy of Cancer (SITC) Meeting in Boston from November 10-12, 2022. Additional investor meetings are scheduled at the Credit Suisse Equity Forum on November 15 and at the Evercore ISI HealthCONx Conference on November 29, where company overviews will be presented.
Positive
- Presentation of initial data from Phase 1 Trial of MP0317 at SITC may generate investor interest.
- Participation in multiple conferences enhances visibility and potential collaborations.
Negative
- No specific financial metrics or outcomes from the Phase 1 Trial provided, which may impact investor confidence.
Details
News Market Reaction – MOLN
The recorded move for MOLN in the trading session of this news was +1.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the team will present at several upcoming investor and scientific conferences.
Initial data from the company’s ongoing Phase 1 Trial of MP0317 for the treatment of solid tumors will be presented as a poster at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12.
The company will also host investor meetings at the Credit Suisse Equity Forum in Zurich, Üetlihof, Switzerland, on November 15; and a corporate presentation at the Evercore ISI HealthCONx Conference in Boston, MA on November 29.
Presentation Details:
Society for Immunotherapy of Cancer Meeting:
Poster: “A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors”
Number: 1475
Timing: November 10, 2022
Credit Suisse Equity Forum:
Company Overview
Timing: November 15, 2022
Evercore ISI HealthCONx Conference:
Company Overview
Timing: Day, November 29, 2022 at 8:00 AM ET
All presentations will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.